She commented that the quantities of data being produced by scientists involved in DNA sequencing exceeded what computers could process at reasonable speeds.

[8][9] By around 2001, Compugen had effected a shift in its business model from a company whose almost exclusive focus was marketing computer programs and applications to one whose operations extended into the diagnostics and therapeutics fields.

Additional endpoints include evaluation of PK/PD and preliminary clinical activity in certain tumor types such as NSCLC, breast, ovarian endometrial cancer.

Under the terms of their license and collaboration agreement, Bayer is responsible for all the clinical development of BAY 1905254 and its future commercialization worldwide, if the therapy is approved.

Under the terms of the agreement, Bristol Bristol-Myers Squibb will supply Opdivo®, its PD-1 inhibitor, for the combination arm of Compugen's Phase 1 study designed to evaluate the safety and tolerability of COM701 and Opdivo in four tumor types, including non-small cell lung, ovarian, breast, and endometrial cancer.

In addition, Bristol-Myers may initiate and fund clinical trials that assess combinations of multiple checkpoint inhibitors, including PVRIG (the target of COM701), and TIGIT.

In conjunction with the collaboration agreement, Bristo-Mayers Squibb made a $12 million equity investment in Compugen, holding approximately 4% of the company.

[18] In August 2013, Compugen entered into a collaboration and license agreement with Bayer AG to develop antibody drugs for cancer immunotherapy against two Compugen-discovered immune checkpoint regulators CGEN-15001T and CGEN-15022.

[23] In December 2014, Compugen announced the initiation of a multi-year research collaboration with Johns Hopkins University School of Medicine, (JHU) on immune checkpoint candidates for the potential treatment of cancer.

The project is overseen by Prof. Drew Pardoll and Dr. Charles Drake, members of Compugen's scientific advisory board and well-known pioneers in the field of immuno-oncology.

[24] In October 2017, the collaboration was expanded to include new additional targets discovered by Compugen which have the potential to serve as a basis for the development of cancer immunotherapy treatments.